Bli medlem
Bli medlem

Du är här

2021-06-17

Field update following the new guidelines in the UK

News: Uppsala, on 17 June 2021. Senzimes distributor comments on the field development following the new guidelines.

In recent communications information on the new launch of the AAGBI guidelines were referenced. These guidelines state that in the UK and Ireland Quantitative neuromuscular monitoring should be used in all cases when neuromuscular blocking (NMB) drugs are administered. An increasing number of Countries in Europe now have different types of recommendations either through guidelines or evidence-based hospital best practices.

Supporting an already high interest from anesthesiologists our distributor in the UK and Ireland has seen a rapid high demand for evaluations of the TetraGraph, which has actually created a waiting list to trial the TetraGraph.

“Our sales team are proud and excited to take the lead in UK and Ireland to support the AAGBI level one recommendation of having an objective monitor in every operating theatre used on every patient receiving NMBs. Patient complications after anaesthesia remains a frequent issue if a quantitative monitor is not used”, says Shelley Dale, National Sales Manager, Healthcare 21.

From the Field Based Sales Team
Its an exciting time to be in Medtech Sales, the Tetragraph is a great product which customers want to see because of the new guidance and fortunately we are able to access hospitals safely once again and show them how the TetraGraph performs” Scott Clissold, Senior Sales Representative Healthcare 21.

Senzimes distributor in the UK (February 2020) and Ireland (April 2021) is Healthcare 21 – owned by Swedish AddLife since April this year. Healthcare 21 recorded sales of about €171 million last year.

TetraGraph is a unique Quantitative digital system based on electromyography that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. Due to its technical versatility, the TetraGraph can be used for all types of surgeries including when the arm needs to be tucked, and in any site since it can follow the patient outside the operating theatre.

For further information, please contact:


Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senzime


Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com

Image Attachments


TetraSens

Attachments


Field update following the new guidelines in the UK

Författare MFN

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.